MORGAN STANLEY (MS) Stock News

Rosen Law Firm is encouraging investors who purchased Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026 to join a class action lawsuit. The lawsuit alleges that Hims made materially false and misleading statements regarding data privacy practices, prescription charging procedures, and regulatory compliance, which subjected the company to potential fees and penalties.

Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company deceptively shared consumers' health data with third-party advertising platforms like Meta and Snap, and violated billing regulations by charging for prescriptions before medical consultations. The stock plunged 14.7% on July 29, 2026, erasing over $970 million in market value.

Strategy Inc. shares rallied 60% over three months, outperforming Bitcoin miners Riot Platforms and CleanSpark, driven by its expanding Bitcoin treasury which reached 848,000 coins. However, the company's extremely high forward P/S ratio of 114.08X and potential share dilution raise valuation concerns, prompting analysts to recommend patience despite improved financial flexibility and cash reserves of $4.88 billion.

The Fidelity MSCI Utilities Index ETF (FUTY) is a low-cost passively managed fund with a 0.08% expense ratio and $2.18 billion in assets. However, it has received a Zacks ETF Rank of 4 (Sell) and is not recommended for investors seeking utilities exposure. The fund has underperformed year-to-date, declining 1.81%, with better alternatives available such as Vanguard Utilities Index Fund ETF Shares (VPU) and State Street Utilities Select Sector SPDR ETF (XLU).

A comprehensive market report on China's stretchers and cots sector forecasts growth through 2033 across ambulance cots, emergency stretchers, manual and motorized transport segments. The report provides historical data from 2018, competitive analysis of key players, and strategic insights for market entry and investment decisions in the medical transport equipment sector.

Rosen Law Firm has filed securities class action lawsuits against Hims & Hers Health, Duolingo, and Ardelyx. The Hims lawsuit alleges the company made false statements regarding data privacy practices, prescription charging procedures, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased securities during specified class periods are encouraged to join the litigation before the November 2, 2026 lead plaintiff deadline.

Morgan Stanley stock declined 1.2% to $187.44, underperforming the S&P 500's 0.47% loss. The stock has fallen 11.91% over the past month, significantly outpacing the Finance sector's 5.13% decline. Ahead of its October 14 earnings report, analysts project Q3 EPS of $2.88 (up 2.86% YoY) and revenue of $19.71 billion (up 8.15% YoY). Morgan Stanley holds a Zacks Rank #3 (Hold) with a Forward P/E of 14.96, trading at a premium to its industry average of 13.08.

Morgan Stanley is expected to report Q3 2026 earnings of $2.88 per share with 8.2% revenue growth, but recent analyst revisions and a negative Earnings ESP of -0.20% suggest limited upside surprise potential. Similarly, Goldman Sachs faces headwinds with an -8.71% Earnings ESP despite expected 9% EPS growth, making both stocks difficult earnings-beat candidates despite their strong historical performance.

Novartis will present Phase III REMODEL-1/-2 trial results for remibrutinib, an oral BTK inhibitor for relapsing multiple sclerosis, at MSToronto2026. The company will also showcase expanded evidence for Kesimpta (ofatumumab) across multiple studies including pediatric MS, treatment-naive patients, and pregnancy/breastfeeding outcomes. An investor call will follow the remibrutinib data presentation.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026.

Quantum BioPharma has entered into a Study Start-Up Agreement with Thermo Fisher Scientific's PPD Clinical Research Business to implement its Phase 2 clinical trial of Lucid-MS, an investigational neuroprotective therapy targeting demyelination in progressive multiple sclerosis. The agreement marks a significant milestone following FDA clearance and represents the initiation of formal study start-up activities.

QUAL is a smart beta ETF launched in 2013 that tracks the MSCI USA Sector Neutral Quality Index with $48.59 billion in assets. It offers broad exposure to U.S. large and mid-cap stocks with a low 0.15% expense ratio and 0.84% dividend yield. The fund is heavily weighted toward Information Technology (40.1%) with top holdings including Microsoft, Apple, and Nvidia. With a beta of 1.00 and 14.20% standard deviation, it represents a medium-risk option that has returned 14.37% year-to-date as of October 2026.

Rosen Law Firm is soliciting investors who purchased securities of Hims & Hers Health, Inc. between August 4, 2025 and July 29, 2026 to join a class action lawsuit. The lawsuit alleges that Hims made materially false statements regarding data privacy practices, prescription charging procedures, and regulatory compliance, which subjected the company to potential fees and penalties.

YieldMax® announced weekly distributions for three Performance & Distribution Target 25 ETFs tracking MSTR, NVDA, and TSLA, with distribution rates of 25.00% and 30-day SEC yields ranging from 0.41% to 3.11%. The distributions are ex-dated October 6, 2026 and payable October 7, 2026. The article emphasizes that distributions are variable and not guaranteed, with significant risks including call writing strategy limitations and single-issuer concentration.

A securities class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making materially false and misleading statements regarding consumer data sharing with third-party advertising platforms, charging for prescriptions before medical consultations, and failing to disclose regulatory scrutiny and potential penalties. The lead plaintiff deadline is November 2, 2026.

Kaplan Fox has filed a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between August 4, 2025 and July 29, 2026. The FTC sued the company for allegedly failing to disclose immediate prescription charges, making subscription cancellations difficult, and sharing consumers' health information with third-party advertising platforms like Meta and Snap. The stock fell 14.73% to $25.00 per share following the FTC action. The lead plaintiff deadline is November 2, 2026.

Schall, Brown & Schwartz LLP announces a securities fraud class action lawsuit against Hims & Hers Health, Inc. for making false and misleading statements regarding customer health data sharing with third-party advertising platforms and treatment practices that could trigger regulatory scrutiny. The class period spans August 4, 2025 to July 29, 2026, with a November 2, 2026 deadline for investors to participate.

Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Hims & Hers Health, Inc. following FTC allegations that the telehealth provider shared consumers' sensitive health information with third-party advertising platforms including Meta and Snap, and engaged in deceptive billing practices. The lawsuit covers securities purchased between August 4, 2025 and July 29, 2026, with a lead plaintiff deadline of November 2, 2026. Hims & Hers shares declined nearly 15% following the FTC announcement.

Law Offices of Howard G. Smith has filed securities fraud class action lawsuits against four publicly-traded companies: Hyliion Holdings Corp., Hims & Hers Health Inc., Unicycive Therapeutics Inc., and Baidu Inc. The lawsuits allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their respective businesses. Investors have until specified deadlines in late October and November 2026 to file lead plaintiff motions.

Recent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. All market attention is now focused on Friday's employment report, which will be a key indicator for future economic policy decisions.

Hims & Hers Health faces a securities class action lawsuit after the FTC alleged the telehealth provider shared consumers' sensitive health information with third-party advertising platforms and engaged in deceptive billing practices. The stock fell 14.73% to $25.00 on July 29, 2026, following the FTC announcement. Investors with losses exceeding $100,000 have until November 2, 2026 to file lead plaintiff applications.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers. The investigations cover Beazer Homes' $33.50/share sale, Colony Bankcorp's merger, Atkore's $95.00/share sale, and Bio Green Med Solution's merger.

Hims & Hers Health (HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company shared consumers' health data with third-party advertisers like Meta and Snap, charged for prescriptions before medical consultations, and violated ROSCA regulations. The stock dropped 14.7% on July 29, 2026, erasing over $970 million in market value. Investors with substantial losses are encouraged to participate in the class action.

Microsoft has attracted investor attention with strong recent performance, returning +1.6% over the past month compared to the S&P 500's -0.4% decline. The company shows solid fundamentals with expected earnings growth of +9.3% for the current fiscal year and +18.4% for the next fiscal year, along with consistent revenue growth projections of +17.4% and +18.3% respectively. However, Microsoft received a Zacks Rank #3 (Hold) rating and a Value Style Score of D, indicating the stock is trading at a premium to peers and may perform in line with the broader market in the near term.

USMV is a large-cap blend ETF with $23.23 billion in assets, offering low-cost exposure to US equities with a 0.15% expense ratio. The fund has returned 4.94% year-to-date and 4.73% over the past year, with a beta of 0.64 indicating lower volatility. It carries a Zacks ETF Rank of 3 (Hold) and is positioned as a suitable option for long-term investors, though alternatives like IVV and VOO offer comparable or lower expense ratios.

The FTC filed a lawsuit against Hims & Hers Health, Inc. on July 29, 2026, alleging the telehealth provider shared consumers' sensitive health information with third-party advertising platforms while claiming to maintain privacy, and deceived users about billing and cancellation practices. The stock declined 14.73% on the news. A class action lawsuit has been filed, with a November 2, 2026 deadline for investors to file lead plaintiff motions.

Rosen Law Firm is soliciting investors who purchased Hims & Hers Health securities between August 4, 2025 and July 29, 2026 to join a class action lawsuit. The lawsuit alleges that Hims made materially false statements regarding data privacy practices, prescription charging procedures, and regulatory compliance, leading to investor damages when the true details became public.

A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making materially false statements about its privacy practices. The FTC accused HIMS of sharing customers' medical information with third-party advertisers including Meta and Snap, and charging consumers for prescriptions without proper consultation. The stock declined 14.73% on the news, dropping $4.32 per share to $25.00 on July 29, 2026.

Robbins LLP announced a class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing customers' protected health information with third-party advertising platforms and engaging in deceptive billing practices. The FTC filed a separate lawsuit on July 29, 2026, which triggered a 14.73% stock decline. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 may be eligible to participate in the class action.

C4 Therapeutics presented biomarker data from its Phase 1 trial of cemsidomide combined with dexamethasone in relapsed/refractory multiple myeloma patients, demonstrating robust T-cell activation and immune cell function. The company also shared preliminary data from a Phase 1b trial combining cemsidomide with elranatamab, showing enhanced CD8+ T-cell expansion and prevention of T-cell exhaustion. The 75 µg dose level was declared safe, allowing advancement to dose escalation and expansion cohorts with full data expected in mid-2027.